The Blood Cancer UK Innovative Clinical Trials Grant 2027 offers up to £8 million for a collaborative trial with the potential to improve survival for people with hard-to-treat leukaemia or myeloid malignancies.
Teams can propose trials of new treatments or combinations, changes to treatment timing or sequencing, or approaches that use biomarkers to guide treatment. A multi-arm, multi-stage design, for example, can test several treatments in parallel and stop arms that show insufficient benefit.
Eligibility and Application Criteria
- Focus on leukaemia or myeloid malignancies with predicted five-year survival below 50% at diagnosis under current care.
- Justify the unmet clinical need and explain how the proposed patient population meets the survival threshold.
- Use a trial design that can adapt while evaluating multiple interventions, and explain why it suits the research question.
- Describe how the results could change clinical practice, including any steps needed for regulatory approval.
- Plan recruitment that reduces barriers for underserved groups and reflects the population the trial aims to help.
- Involve diverse patient and public representatives in designing and delivering the trial.
Funding Details
- Typical award: £5 million to £8 million.
- Maximum request: £8 million.
- Duration: Normally up to seven years.
- Number of awards: One trial planned for this round.
Deadline
- Mandatory introductory call: By the end of December 2026.
- Applicant workshop: Expected in January 2027.
- Expression of interest: March 25, 2027, at 3:00 p.m. GMT.
- Invited full applications: Expected in December 2027.